
    
      Objectives for this study are two-fold:

        1. To determine the efficacy of SCH66336 in patients with chronic phase and accelerated
           phase CML in relation to response rate, duration of response, and survival.

        2. To assess the toxicity of SCH66366 in these patients.
    
  